Screener / SEC EDGAR /CIK 0001638833 /10-K filed Mar 2, 2026, compared with Mar 7, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Hospitals

Surgery Partners, Inc. SGRY

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 0 above the last range given
Within the range 1 of 1 range targets
Below the range 0 below the last range given
Minimums and caps kept 1 of 1 "at least" and "no more than" targets

The numbers SGRY said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
EBITDA (company-defined)
Fiscal 2026
Given at least $530.00M release Mar 2, 2026
Kept at least $530.00M release May 5, 2026
Kept at least $530.00M release Aug 10, 2026
– No standard number
The company's words
Initial 2026 guidance (excluding M&A) for Adjusted EBITDA of at least $530 million with revenue in the range of $3.35 billion to $3.45 billion release Mar 2, 2026
REAFFIRMS FULL YEAR 2026 GUIDANCE … Full year 2026 revenue guidance reaffirmed to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million release May 5, 2026
REAFFIRMS FULL YEAR 2026 GUIDANCE … Full year 2026 revenue guidance reaffirmed to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million, excluding recently disclosed pending divestiture release Aug 10, 2026
Revenue
Fiscal 2026
Given $3.35B to $3.45B release May 5, 2026
Kept $3.35B to $3.45B release Aug 10, 2026
– Not reported yet
The company's words
Full year 2026 revenue guidance reaffirmed to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million release May 5, 2026
Full year 2026 revenue guidance reaffirmed to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million, excluding recently disclosed pending divestiture release Aug 10, 2026
EBITDA (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $555.00M to $565.00M release Mar 3, 2025
Raised $3.30B to $3.45B release May 12, 2025
Kept $3.30B to $3.45B release Aug 5, 2025
Lowered $3.27B to $3.30B release Nov 10, 2025
– No standard number
The company's words
FULL YEAR 2024 RESULTS; SETS 2025 GUIDANCE … Full year 2025 revenue expected to be in the range of $3.30 billion to $3.45 billion and Adjusted EBITDA expected to be in the range of $555 million to $565 million release Mar 3, 2025
Full year 2025 revenue and Adjusted EBITDA guidance reaffirmed to be in the range of $3.30 billion to $3.45 billion and $555 million to $565 million, respectively release May 12, 2025
Full year 2025 revenue and Adjusted EBITDA guidance reaffirmed to be in the range of $3.30 billion to $3.45 billion and $555 million to $565 million, respectively release Aug 5, 2025
Full year 2025 revenue and Adjusted EBITDA guidance to be in the range of $3.275 billion to $3.30 billion and $535 million to $540 million, respectively release Nov 10, 2025
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $3.30B to $3.45B release Mar 3, 2025
$3.31B
10-K filed 2026-03-02
Within the range
The company's words
Full year 2025 revenue expected to be in the range of $3.30 billion to $3.45 billion and Adjusted EBITDA expected to be in the range of $555 million to $565 million release Mar 3, 2025
EBITDA (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given at least $495.00M release Feb 26, 2024
Raised at least $3.08B release Nov 12, 2024
– No standard number
The company's words
Revenue for 2024 expected to be greater than $3.0 billion and Adjusted EBITDA expected to be greater than $495 million release Feb 26, 2024
Full year 2024 revenue and Adjusted EBITDA guidance reaffirmed at greater than $3.075 billion and greater than $508 million, respectively release Nov 12, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given at least $3.00B release Feb 26, 2024
Raised at least $3.05B release May 7, 2024
Raised at least $3.08B release Aug 6, 2024
$3.11B
10-K filed 2025-03-07
At or above the minimum
The company's words
Revenue for 2024 expected to be greater than $3.0 billion and Adjusted EBITDA expected to be greater than $495 million release Feb 26, 2024
The Company raised its outlook for 2024 revenues to be at least $3.05 billion and projects 2024 Adjusted EBITDA to be at least $505 million. release May 7, 2024
The Company raised its outlook for 2024 revenues to be greater than $3.075 billion and projects 2024 Adjusted EBITDA to be greater than $508 million. release Aug 6, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-26), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SGRY/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.